FEATURED NEWS

• Key Excerpts from IG Review of the DEA's Efforts to Control the Diversion of Opioids

  October 1, 2019

  The following are excerpts from the recent report by the Office of the Inspector General, U.S. Department of Justice on the Drug Enforcement Administration’s (DEA) regulatory and enforcement efforts to control the diversion of opioids.

• HDA Statement on Inspector General's DEA Report

  October 1, 2019

  In response to the release of the U.S. Department of Justice Office of the Inspector General's Review of the Drug Enforcement Administration’s (DEA) Regulatory and Enforcement Efforts to Control the Diversion of Opioids, John Parker, Senior Vice President of Communications with the Healthcare Distribution Alliance (HDA) released the following statement.

• HDA Statement on the Ensuring Patient Access and Effective Drug Enforcement Act

  September 13, 2019

  The Healthcare Distribution Alliance (HDA) released the following statement regarding media reporting on the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.

• Important Context About the Ensuring Patient Access and Effective Drug Enforcement Act

  September 12, 2019

  The fundamental premise of recent media coverage — that the passage of the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 (EPAEDEA) weakened the Drug Enforcement Administration’s (DEA) enforcement authority during the opioid crisis — is factually incorrect.

• HDA Statement on HHS-FDA "Safe Importation Action Plan"

  July 31, 2019

  The Healthcare Distribution Alliance (HDA) released the following statement on the release of the “Safe Importation Action Plan” by the Department of Health and Human Services (HHS) and U.S. Food and Drug Administration (FDA).